<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542958505895">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">23.11.2018 07:35:05 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.1ipxl6q8c1mue</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I went to  &lt;a href=&quot;http://lemcasesorias.com/index.php/clotrimazole-and-betamethasone-goodrx-83f5.pdf#mock&quot;&gt;clotrimazole and betamethasone goodrx&lt;/a&gt;  The rumours began after Bloomberg reported that the Swiss major was seeking finance to buy Alexion, which currently has one marketed product. That is Soliris (eculizumab), approved for paroxysmal nocturnal haemoglobinuria, an ultra-rare and life-threatening blood disorder, and as the only treatment for patients for atypical haemolytic uraemia syndrome.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
